3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Keratosis, Actinic
25
Uterine Cervical Dysplasia
13
Melanoma
10
Carcinoma, Basal Cell
10
Glioma
6
Glioblastoma
6
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Neoplasm Metastasis
4
Condylomata Acuminata
4
Precancerous Conditions
3
Papillomavirus Infections
3
Keratosis
3
Hutchinson's Melanotic Freckle
3
Vulvar Neoplasms
2
Urinary Bladder Neoplasms
2
Squamous Intraepithelial Lesions
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasms
2
Hemangioma, Capillary
2
HIV Infections
2
Ependymoma
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Warts
1
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
1
Virus Diseases
1
Vaginal Neoplasms
1
Stomach Neoplasms
1
Interventions
Oxaliplatin
290
Capecitabine
206
Fluorouracil
181
Cisplatin
168
Docetaxel
138
S 1 (combination)
132
Paclitaxel
121
Leucovorin
116
Irinotecan
106
pembrolizumab
103
Trastuzumab
71
apatinib
56
Nivolumab
56
sintilimab
45
Drug Therapy
43
Surgical Procedures, Operative
37
Radiotherapy
37
Bevacizumab
37
Ramucirumab
34
titanium silicide
31
Hyperthermic Intraperitoneal Chemotherapy
30
Epirubicin
30
Carboplatin
30
tislelizumab
28
Cyclophosphamide
27
XELOX
24
Tegafur
23
Folfox protocol
22
Albumin-Bound Paclitaxel
22
camrelizumab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Stomach Neoplasms
×
Imiquimod
×
Clear all
NCT02276300
2019-11-20
HER2
Technical University of Munich
Phase 1
Completed
2 enrolled